Cargando…

Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention

OBJECTIVE: To compare quantitatively different recommended goals for cholesterol-lowering treatment in the primary prevention of atherosclerotic cardiovascular disease (ASCVD). DESIGN: Outcomes at pretreatment low-density lipoprotein (LDL) cholesterol concentrations from 2 to 5 mmol/L and 10-year AS...

Descripción completa

Detalles Bibliográficos
Autores principales: Soran, Handrean, Adam, Safwaan, Iqbal, Zohaib, Durrington, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131112/
https://www.ncbi.nlm.nih.gov/pubmed/35613766
http://dx.doi.org/10.1136/bmjopen-2021-050266
_version_ 1784713116498526208
author Soran, Handrean
Adam, Safwaan
Iqbal, Zohaib
Durrington, Paul
author_facet Soran, Handrean
Adam, Safwaan
Iqbal, Zohaib
Durrington, Paul
author_sort Soran, Handrean
collection PubMed
description OBJECTIVE: To compare quantitatively different recommended goals for cholesterol-lowering treatment in the primary prevention of atherosclerotic cardiovascular disease (ASCVD). DESIGN: Outcomes at pretreatment low-density lipoprotein (LDL) cholesterol concentrations from 2 to 5 mmol/L and 10-year ASCVD risk from 5% to 30% were modelled, using the decrease in risk ratio per mmol/L reduction in LDL cholesterol derived from randomised controlled trials (RCTs) of cholesterol-lowering medication. DATA SOURCE: Summary statistics from 26 RCTs comparing treatment versus placebo or less versus more effective treatment and 12 RCTs in which statin was compared with a higher dose of the same statin or with a similar statin dose to which an adjunctive cholesterol-lowering drug was added. SETTING: The different recommended goals are: (1) LDL cholesterol≤2.6 mmol/L (100 mg/dL); (2) LDL cholesterol≤1.8 mmol/L (70 mg/dL); (3) non-high density lipoprotein (HDL) cholesterol decrease of ≥40%; or (4) LDL cholesterol≤1.8 mmol/L (70 mg/dL) or decreased by ≥50% whichever is lower. PARTICIPANTS: RCT participants. INTERVENTIONS: Statins alone or in combination with ezetimibe or proprotein convertase subtilisin/kexin type 9 inhibitors. MAIN OUTCOME MEASURES: For each of the recommended therapeutic goals, our primary outcome was the number of events prevented per 100 people treated for 10 years (N(100)) and the number of needed to treat (NNT) to prevent one event over 10 years. RESULTS: At pretreatment LDL cholesterol 4–5 mmol/L, all four goals provided similar benefit with N(100) 1.47–16.45 (NNT 6–68), depending on ASCVD risk and pretreatment LDL cholesterol. With initial LDL cholesterol in the range 2–3 mmol/L, the target of 2.6 mmol/L was the least effective with N(100) between 0 and 2.84 (NNT 35–infinity). The goal of 1.8 mmol/L was little better. However, reductions in non-HDL cholesterol by ≥40% or of LDL cholesterol to 1.8 mmol/L and/or by 50%, whichever is lower, were more effective, delivering N(100) of between 0.9 and 9.33 (NNT 11–111). Percentage decreases in LDL cholesterol or non-HDL cholesterol concentration are more effective targets than absolute change in concentration in people with initial values of <4 mmol/L. CONCLUSIONS: The LDL cholesterol target of 1.8 mmol/L is most effective when initial LDL cholesterol is >4 mmol/L. The time has probably come for the LDL cholesterol goal of <2.6 mmol/L to be abandoned.
format Online
Article
Text
id pubmed-9131112
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91311122022-06-09 Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention Soran, Handrean Adam, Safwaan Iqbal, Zohaib Durrington, Paul BMJ Open Diabetes and Endocrinology OBJECTIVE: To compare quantitatively different recommended goals for cholesterol-lowering treatment in the primary prevention of atherosclerotic cardiovascular disease (ASCVD). DESIGN: Outcomes at pretreatment low-density lipoprotein (LDL) cholesterol concentrations from 2 to 5 mmol/L and 10-year ASCVD risk from 5% to 30% were modelled, using the decrease in risk ratio per mmol/L reduction in LDL cholesterol derived from randomised controlled trials (RCTs) of cholesterol-lowering medication. DATA SOURCE: Summary statistics from 26 RCTs comparing treatment versus placebo or less versus more effective treatment and 12 RCTs in which statin was compared with a higher dose of the same statin or with a similar statin dose to which an adjunctive cholesterol-lowering drug was added. SETTING: The different recommended goals are: (1) LDL cholesterol≤2.6 mmol/L (100 mg/dL); (2) LDL cholesterol≤1.8 mmol/L (70 mg/dL); (3) non-high density lipoprotein (HDL) cholesterol decrease of ≥40%; or (4) LDL cholesterol≤1.8 mmol/L (70 mg/dL) or decreased by ≥50% whichever is lower. PARTICIPANTS: RCT participants. INTERVENTIONS: Statins alone or in combination with ezetimibe or proprotein convertase subtilisin/kexin type 9 inhibitors. MAIN OUTCOME MEASURES: For each of the recommended therapeutic goals, our primary outcome was the number of events prevented per 100 people treated for 10 years (N(100)) and the number of needed to treat (NNT) to prevent one event over 10 years. RESULTS: At pretreatment LDL cholesterol 4–5 mmol/L, all four goals provided similar benefit with N(100) 1.47–16.45 (NNT 6–68), depending on ASCVD risk and pretreatment LDL cholesterol. With initial LDL cholesterol in the range 2–3 mmol/L, the target of 2.6 mmol/L was the least effective with N(100) between 0 and 2.84 (NNT 35–infinity). The goal of 1.8 mmol/L was little better. However, reductions in non-HDL cholesterol by ≥40% or of LDL cholesterol to 1.8 mmol/L and/or by 50%, whichever is lower, were more effective, delivering N(100) of between 0.9 and 9.33 (NNT 11–111). Percentage decreases in LDL cholesterol or non-HDL cholesterol concentration are more effective targets than absolute change in concentration in people with initial values of <4 mmol/L. CONCLUSIONS: The LDL cholesterol target of 1.8 mmol/L is most effective when initial LDL cholesterol is >4 mmol/L. The time has probably come for the LDL cholesterol goal of <2.6 mmol/L to be abandoned. BMJ Publishing Group 2022-05-23 /pmc/articles/PMC9131112/ /pubmed/35613766 http://dx.doi.org/10.1136/bmjopen-2021-050266 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Diabetes and Endocrinology
Soran, Handrean
Adam, Safwaan
Iqbal, Zohaib
Durrington, Paul
Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention
title Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention
title_full Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention
title_fullStr Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention
title_full_unstemmed Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention
title_short Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention
title_sort mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention
topic Diabetes and Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131112/
https://www.ncbi.nlm.nih.gov/pubmed/35613766
http://dx.doi.org/10.1136/bmjopen-2021-050266
work_keys_str_mv AT soranhandrean mathematicalmodellingofthemosteffectivegoalofcholesterolloweringtreatmentinprimaryprevention
AT adamsafwaan mathematicalmodellingofthemosteffectivegoalofcholesterolloweringtreatmentinprimaryprevention
AT iqbalzohaib mathematicalmodellingofthemosteffectivegoalofcholesterolloweringtreatmentinprimaryprevention
AT durringtonpaul mathematicalmodellingofthemosteffectivegoalofcholesterolloweringtreatmentinprimaryprevention